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do	 not	 seek	medical	 care,	 even	 if	 they	 have	 access	 to	 a	 healthcare	















minologies	 and	 definitions	 of	 normal	menstrual	 parameters,	 and	 the	
symptoms	of	AUB	were	initially	published	in	2007,15,16	while	the	sem-








in	 Fertility	 Sterility	 and	 Human	 Reproduction,15,16 recommended a 
substantial	 revision	of	existing	 terminologies	and	definitions	 for	 the	




used	 internationally	 in	 a	 disparate	 manner,	 and	 had	 no	 consistent	
meaning	for	the	general	and	academic	communities.15–17
The	 second	 key	 publication14	 presented	 a	 novel	 and	 pragmatic	
approach	 to	 classification	 of	 the	 underlying	 causes	 of	AUB	 in	 non-	
pregnant	 women.	 No	 such	 systematic	 classification	 of	 underlying	
causes	 existed	 at	 that	 time.	 This	 2011	 manuscript	 introduced	 the	
PALM-	COEIN	 classification	 based	 on	 clinical-	 and	 imaging-	based	
stratification	 of	 causes	 into	 “structural”	 pathologies	 that	 can	 be	
“imaged”	 and/or	 defined	 histopathologically	 (Polyps,	 Adenomyosis,	
Leiomyomas	 and	 Malignancy	 or	 atypical	 endometrial	 hyperplasia;	
PALM).	 The	 remaining	 causes	were	 categorized	 as	 “non-	structural”,	
in	that	they	cannot	be	 imaged,	but	clinical	assessment	with	detailed	



















that	 include	use	of	a	modified	RAND	Delphi	process	applied	 to	 the	
attendees	of	a	series	of	FIGO	Menstrual	Disorders	Committee	(MDC)	
















2  | ACUTE VERSUS CHRONIC 
NONGESTATIONAL AUB IN THE 
REPRODUCTIVE YEARS
In	 the	 original	 system,14	 FIGO	 introduced	 the	 concept	 of	 nonges-
tational	acute	AUB	 in	 the	 reproductive	years,	distinguishing	 it	 from	
chronic	 AUB—an	 approach	 endorsed	 by	 the	 American	 College	





other	 hand,	 is	 defined	 as	 an	 episode	of	 heavy	bleeding	 that,	 in	 the	
opinion	of	the	clinician,	is	of	sufficient	quantity	to	require	immediate	
intervention	to	minimize	or	prevent	further	blood	loss.	Acute	heavy	
menstrual	 bleeding	 may	 present	 in	 the	 context	 of	 existing	 chronic	
AUB	or	can	occur	in	the	absence	of	such	a	background	history.
3  | FIGO- AUB SYSTEM 1
3.1 | Revision of terminologies and definitions of 
symptoms of abnormal uterine bleeding
The	 revised	 FIGO-	AUB	 System	1	 is	 seen	 in	 Figure	1,	with	 changes	
summarized	 in	Table	1.	As	determined	by	 the	multinational	process	
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described	 in	 the	original	publications,14–16	 terms	such	as	menorrha-
gia,	metrorrhagia,	 oligomenorrhea,	 and	dysfunctional	 uterine	 bleed-
ing	have	been	abandoned.	There	is	acknowledgement	of	the	specific	
changes	 in	 menstrual	 bleeding	 patterns	 that	 may	 be	 encountered	
at	 each	 end	 of	 the	 reproductive	 spectrum	 (i.e.	 in	 adolescence	 or	
the	peri-	menopause).26










tion	 is	up	 to	20	days,	 to	variation	of	7–9	days,	depending	upon	age	
(18–25	years	≤9	days;	26–41	years	≤7	days;	42–45	years	≤9	days).27 





which	 interferes	 with	 a	 woman’s	 physical,	 social,	 emotional	 and/or	
material	quality	of	life”.5,28
4  | FIGO AUB SYSTEM 2
4.1 | Revision of classification of underlying causes 
of AUB (PALM- COEIN)
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categories,	 arranged	 according	 to	 the	 acronym	 PALM-	COEIN	 (pro-
nounced	“palm-	koin”):	Polyp;	Adenomyosis;	Leiomyoma;	Malignancy	
and	hyperplasia;	Coagulopathy;	Ovulatory	 dysfunction;	 Endometrial	

















Since	 the	original	publication	of	 the	FIGO	AUB	systems,14	 there	
have	been	advances	in	the	diagnosis	of	adenomyosis,	although	its	rela-
tionship	 to	 reproductive	 function	and	uterine	bleeding	 is	 still	under	
investigation.	 It	has	been	demonstrated	that	two-	dimensional	trans-
vaginal	ultrasonography	has	similar	sensitivity	and	specificity	for	the	
diagnosis	 of	 adenomyosis	 when	 compared	 to	 magnetic	 resonance	
imaging	 (MRI).29,30	 There	 is	 some	 progress	 regarding	 the	 spectrum	
of	 two-	dimensional	 ultrasonography	 findings	 associated	 with	 the	


















lap.	 It	 is	 also	 recognized	 that	 there	are	 some	difficulties	 in	 applying	
the	leiomyoma	subclassification	system	to	the	spectrum	of	 leiomyo-



























Abbreviations:	 FIGO,	 International	 Federation	 of	 Gynecology	 and	



























Abbreviations:	 AUB,	 abnormal	 uterine	 bleeding;	 FIGO,	 International	
Federation	of	Gynecology	and	Obstetrics.












ume	based	on	 imaging	 (transabdominal	or	 transvaginal	ultrasonogra-
phy	or	MRI),	as	well	as	an	estimate	of	the	number	of	leiomyomas	(1,	2,	
3,	4,	or	greater	 than	4).	 If	such	 imaging	 is	not	available,	such	as	may	



























Women	 with	 AUB	 and	 associated	 malignant	 or	 premalignant	














revision,	 they	 are	 considered	 iatrogenic	 and	 classified	 as	AUB-	I.	This	





defined.	These	 include,	but	 are	not	 limited	 to,	 entities	 such	as	 arte-
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cervical	 niche	 or	 “isthmocele”	 frequently	 found	 in	 association	 with	








value	 to	 specialists	 and	 researchers,	 it	 should	 have	 utility	 for	 any	
healthcare	provider.
This	 approach	 has	 been	 designed	 following	 the	 example	 of	 the	
WHO	 TNM	 staging	 of	 malignant	 tumors,	 with	 each	 component	









































When	 evaluating	 a	woman	 of	 reproductive	 age	with	 either	 acute	
or	 chronic	 genital	 tract	 bleeding	 thought	 to	be	AUB,	 the	 clinician	
should	 ensure	 that	 the	 bleeding	 is	 not	 related	 to	 pregnancy,	 and	
is	emanating	 from	the	cervical	canal,	 rather	 than	another	 location	
such	as	the	vagina,	vulva,	perineum,	or	perianal	region.	Pregnancy	
may	be	reliably	confirmed	with	a	urine	or	serum	assay	for	the	pres-
ence	 of	 the	 β-	subunit	 of	 human	 chorionic	 gonadotropin	 (hCG).	 It	








patient	 for	 each	 of	 the	 components	 of	 FIGO	AUB	 System	 2,	 the	
PALM-	COEIN	classification.
6.2 | Determination of ovulatory status




If,	 largely	 based	 on	 FIGO	AUB	 System	 1,	 a	woman	 is	 found	 to	
have	AUB	related	to	a	ovulatory	disorder,	she	is	to	be	categorized	as	
AUB-	O.	 If	 there	 is	 uncertainty	 regarding	 ovulatory	 status,	measure-
ment	of	serum	progesterone,	timed	to	the	best	estimate	of	mid-	luteal	
phase,	may	 be	 useful	 for	 confirming	 ovulation	 in	 the	 current	 cycle.	
Whereas	 endometrial	 biopsy	 is	 not	 recommended	 as	 a	method	 for	
determination	of	ovulatory	status,	when	performed	and	appropriately	
indicated—to	evaluate	for	the	presence	of	premalignant	or	malignant	
endometrial	 change—histopathological	 findings	 reflecting	 secretory	
change	may	confirm	that	ovulation	has	occurred.
6.3 | Screening for systemic disorders of hemostasis
A	 structured	history	 is	 a	 useful	 and	effective	 screening	 tool.	 FIGO	
suggests	a	 tool	 that	has	been	demonstrated	 to	have	90%	sensitiv-
ity	 for	 the	detection	of	 these	 relatively	 common	disorders	 (coagu-
lopathies)44	 (Table	3).	 For	 those	 with	 a	 positive	 screening	 result,	
further	 testing	 is	 necessary,	 often	 following	 consultation	 with	 a	
physician	with	a	special	interest	in	disorders	of	coagulation,	such	as	
a	 hematologist.	 Such	 tests	may	 include	 assays	 for	 von	Willebrand	
factor,	 Ristocetin	 cofactor,	 partial	 thromboplastin	 time	 (PTT)	 and	





6.4 | Evaluation of the endometrium
Endometrial	 sampling	 is	not	 required	 for	 all	 patients	with	AUB,	 so	
it	is	necessary	to	identify	the	women	for	whom	endometrial	biopsy	
is	 appropriate.	 Selection	 for	 endometrial	 sampling	 is	 based	 on	





endometrial	 sampling	 be	 considered	 for	 all	 women	 over	 a	 certain	
age,	usually	45	years.5	It	is	also	evident	that	obesity	contributes	sig-






















6.5 | Evaluation of the structure of the 
endometrial cavity
Evaluation	 for	 structural	 abnormalities	 affecting	 the	 endometrial	




early	 in	the	course	of	the	 investigation.	 Ideally,	the	ultrasonography	
system	must	be	of	adequate	quality	to	clearly	display	both	myometrial	
and	endometrial	 features,	 and	 the	examiner	 should	have	 the	ability	
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endometrial	polyp(s),	 if	 there	are	 leiomyomas	 that	may	encroach	on	
the	 endometrial	 cavity,	 or	 if	 the	 examination	 is	 suboptimal,	 imag-
ing	 with	 more	 sensitive	 techniques	 is	 recommended.	 These	 gener-









In	 some	 parts	 of	 the	world,	 notably	 in	 the	UK	 (managed	 by	 the	
British	National	Health	Service),	 there	 is	 an	emphasis	on	conducting	
investigation	 and	management	 of	 the	 symptom	 of	HMB	 at	 the	 first	
consultation	(“One	stop	management”,	including	key	history,	examina-







encountered	 with	 adolescents	 and	 virginal	 women,	 TVUS,	 contrast	
sonohysterography,	 and	office	hysteroscopy	may	not	 be	 feasible.	 In	
such	 instances,	 there	 is	 a	 role	 for	MRI.	Alternatively,	 hysteroscopic	





terography.	Usually,	 a	 patient	may	 be	 categorized	with	 one	 or	more	
submucous	 leiomyomas	 (AUB-	LSM)	 with	 either	 sonohysterography	
or	hysteroscopy.	When	using	either,	 the	clinician	should	take	care	to	
infuse	 the	 distending	medium	with	 low	 pressure	 so	 that	 the	 natural	






























assignment	 of	AUB-	A	 is	 best	 based	 on	 imaging	 findings	 consistent	





















































based	 on	 6	years	 of	 analysis,	 discussion,	 and	 debate	 since	 the	
original	 publication.	 The	 original	 seminal	 publications	 presented	
effective	approaches	to	the	terminologies	and	definitions	around	
AUB	(System	1),	followed	by	development	of	a	novel	classification	
(PALM-	COEIN)	 of	 underlying	 causes	 of	 abnormal	 uterine	 bleed-
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TABLE  3 Screening	instrument	for	coagulopathies	in	women	with	
the	symptom	of	heavy	menstrual	bleeding.a,b
Initial screening for an underlying disorder of hemostasis in patients 
with excessive menstrual bleeding should be by a structured history. 
















evaluation	 including	 consultation	with	 a	 hematologist	 and/or	 testing	 of	
von	Willebrand	factor	and	Ristocetin	cofactor.
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